Literature DB >> 28657510

Results of Screening in Familial Non-Medullary Thyroid Cancer.

Joanna Klubo-Gwiezdzinska1, Lily Yang2, Roxanne Merkel2, Dhaval Patel2, Naris Nilubol2, Maria J Merino3, Monica Skarulis1, Samira M Sadowski2,4, Electron Kebebew2,5.   

Abstract

BACKGROUND: Although a family history of thyroid cancer is one of the main risk factors for thyroid cancer, the benefit of screening individuals with a family history of thyroid cancer is not known.
METHODS: A prospective cohort study was performed with yearly screening using neck ultrasound and fine-needle aspiration biopsy of thyroid nodule(s) >0.5 cm in at-risk individuals whose relatives were diagnosed with familial non-medullary thyroid cancer (FNMTC). The eligibility criteria were the presence of thyroid cancer in two or more first-degree relatives and being older than seven years of age. Twenty-five kindred were enrolled in the study (12 families with two members affected, and 13 with three or more members affected at enrollment).
RESULTS: Thyroid cancer was detected by screening in 4.6% (2/43) of at-risk individuals from families with two members affected, and in 22.7% (15/66) of at-risk members from families with three or more patients affected (p = 0.01). FNMTC detected by screening was characterized by a smaller tumor size (0.7 ± 0.5 cm vs. 1.5 ± 1.1 cm; p = 0.006), a lower rate of central neck lymph node metastases (17.6% vs. 51.1%; p = 0.02), less extensive surgery (hemithyroidectomy 23.5% vs. 0%; p = 0.002), and a lower rate of radioactive iodine therapy (23.5% vs. 79%; p < 0.001) compared to those affected at enrollment.
CONCLUSIONS: Screening of at-risk family members resulted in earlier detection of low-risk FNMTC and was associated with a less aggressive initial treatment. Screening with thyroid ultrasound should be considered in kindred with three or more family members affected by FNMTC. Since active screening might be associated with the risk of overtreatment, it should be implemented with caution, specifically in elderly individuals.

Entities:  

Keywords:  familial; screening; thyroid cancer; thyroidectomy; ultrasound

Mesh:

Year:  2017        PMID: 28657510      PMCID: PMC5564020          DOI: 10.1089/thy.2016.0668

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  33 in total

1.  Does familial non-medullary thyroid cancer adversely affect survival?

Authors:  Frederic Triponez; Mariwil Wong; Cord Sturgeon; Nadine Caron; David G Ginzinger; Mark R Segal; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Korea's thyroid-cancer "epidemic"--screening and overdiagnosis.

Authors:  Hyeong Sik Ahn; Hyun Jung Kim; H Gilbert Welch
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

4.  Aggressiveness in familial nonmedullary thyroid carcinoma--the controversy continues.

Authors:  Haggi Mazeh; Rebecca S Sippel
Journal:  Thyroid       Date:  2014-04       Impact factor: 6.568

5.  Familial nonmedullary thyroid carcinoma: a meta-review of case series.

Authors:  K C Loh
Journal:  Thyroid       Date:  1997-02       Impact factor: 6.568

6.  Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population.

Authors:  Shinya Uchino; Shiro Noguchi; Hitoshi Kawamoto; Hiroyuki Yamashita; Shin Watanabe; Hiroto Yamashita; Shigeru Shuto
Journal:  World J Surg       Date:  2002-04-30       Impact factor: 3.352

7.  Family Screening in Familial Papillary Carcinoma: The Early Detection of Thyroid Disease.

Authors:  Antonio Ríos; J M Rodríguez; D Navas; A Cepero; N M Torregrosa; M D Balsalobre; P Parrilla
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

8.  Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.

Authors:  M Capezzone; S Marchisotta; S Cantara; G Busonero; L Brilli; K Pazaitou-Panayiotou; A F Carli; G Caruso; P Toti; S Capitani; A Pammolli; F Pacini
Journal:  Endocr Relat Cancer       Date:  2008-10-02       Impact factor: 5.678

Review 9.  An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up.

Authors:  Rebecca S Sippel; Nadine R Caron; Orlo H Clark
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery.

Authors:  Hitomi Oda; Akira Miyauchi; Yasuhiro Ito; Kana Yoshioka; Ayako Nakayama; Hisanori Sasai; Hiroo Masuoka; Tomonori Yabuta; Mitsuhiro Fukushima; Takuya Higashiyama; Minoru Kihara; Kaoru Kobayashi; Akihiro Miya
Journal:  Thyroid       Date:  2015-11-05       Impact factor: 6.568

View more
  14 in total

Review 1.  An update on familial nonmedullary thyroid cancer.

Authors:  Sabrine A Ammar; Wilson M Alobuia; Electron Kebebew
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

2.  Long non-coding RNA H19 knockdown inhibits the cell viability and promotes apoptosis of thyroid cancer cells through regulating the PI3K/AKT pathway.

Authors:  Xiaoyu Li; Qinghuai Li; Xiao Jin; Hao Guo; Yong Li
Journal:  Exp Ther Med       Date:  2019-07-01       Impact factor: 2.447

3.  Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

Authors:  Mustapha El Lakis; Andreas Giannakou; Pavel J Nockel; Douglas Wiseman; Sudheer Kumar Gara; Dhaval Patel; Zahraa Abdul Sater; Yevgeniya Y Kushchayeva; Joanna Klubo-Gwiezdzinska; Naris Nilubol; Maria J Merino; Electron Kebebew
Journal:  Surgery       Date:  2018-10-14       Impact factor: 3.982

4.  Bibliometric analysis of research on thyroid ultrasonography.

Authors:  Juan Su; Guanghui Gao; Hongxia Xu
Journal:  Gland Surg       Date:  2021-12

5.  Epidemiology of Thyroid Cancer.

Authors:  Cari M Kitahara; Arthur B Schneider
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-07-01       Impact factor: 4.090

6.  Single liver metastasis of a follicular variant of papillary thyroid carcinoma: a rare pattern of organ spread.

Authors:  Viviana Ostrovsky; Barak Bar-Zakai; Rafael Miller; Tal Schiller; Alena Kirzhner; Hilla Knobler; Taiba Zornitzki
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-08-20

Review 7.  Genetic testing in endocrine surgery: Opportunities for precision surgery.

Authors:  Wilson Alobuia; Justin Annes; Electron Kebebew
Journal:  Surgery       Date:  2020-05-04       Impact factor: 3.982

8.  Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma.

Authors:  Marco Capezzone; Noemi Fralassi; Chiara Secchi; Silvia Cantara; Lucia Brilli; Tania Pilli; Fabio Maino; Raffaella Forleo; Furio Pacini; Gabriele Cevenini; Alessandra Cartocci; Maria Grazia Castagna
Journal:  Eur Thyroid J       Date:  2020-04-28

9.  Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.

Authors:  Junwei Zhu; Kaile Wu; Zhangying Lin; Suwen Bai; Jing Wu; Peikun Li; Haowei Xue; Juan Du; Bing Shen; Huiyin Wang; Yehai Liu
Journal:  Mol Genet Genomic Med       Date:  2019-10-22       Impact factor: 2.183

10.  Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study.

Authors:  Susan Shafiei; Mehrdokht Sadrolodabaei; Atena Aghaei; Narjess Ayati; Samira Zare Namdar; Donya Hemati; Seyed Rasoul Zakavi
Journal:  Int J Endocrinol Metab       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.